Cardiovascular Health

Discover how triple combination therapy for hypertension enhances cardiovascular health, as endorsed by the AHA and supported by pharmacists.

Hypertensive disorders of pregnancy confer increased cardiovascular risk, with heightened risk corresponding to more severe hypertension.

Heart failure prevention can be integrated into health systems to optimize care.

Explore the critical role of pharmacists in improving cardiovascular health and addressing mortality trends in underserved communities.

A new drug, DR10624, shows promise in reducing triglycerides and liver fat, offering hope for patients with severe hypertriglyceridemia and fatty liver disease.

Explore the link between chronic kidney disease and cardiovascular risk, highlighting the importance of GFR and albuminuria in patient care.

Explore the need for integrated approaches in cardiovascular and kidney health to combat rising mortality rates and improve patient outcomes.

Discover how Sotatercept impacts cardiovascular health and its potential benefits for patients with pulmonary arterial hypertension (PAH) in this insightful article.

Pharmacists play a vital role in managing cardiovascular health, addressing medication adherence, and educating patients, said Zia Ul Haq, MPH, MBBS.

SGLT2 inhibitors significantly reduce atrial fibrillation risk and improve heart failure outcomes, outperforming GLP-1 agonists in cardiovascular benefits.

Maintaining cardiovascular health significantly reduces dementia risk in adults with type 2 diabetes, highlighting the heart-brain connection for cognitive protection.

Combining GLP-1 RA therapy with healthy lifestyle habits significantly reduces cardiovascular risk in type 2 diabetes patients, enhancing heart health outcomes.

Craig Beavers and Kyle Fischer, PharmD, BCCP, MBA, discuss key late-breaking cardiovascular trials expected at the American Heart Association’s upcoming annual meeting, exploring their clinical relevance and implications for pharmacists.

Long-term melatonin use for insomnia raises heart failure risks, highlighting the need for careful evaluation of sleep aids and underlying health issues.

Teva Pharmaceuticals recalls over 580,000 bottles of prazosin due to contamination concerns, urging patients to consult healthcare providers.

Richard Kovacs, MD, underscores the pharmacist’s role in educating patients about sodium reduction, monitoring blood pressure, and ensuring safe transitions to low-sodium oxybate therapy.

Richard Kovacs, MD, explains how switching from high-sodium to low-sodium oxybate led to meaningful blood pressure reductions and lower cardiovascular risk in patients with narcolepsy.

In Danish athletes, long-term anabolic androgenic steroid use was associated with progressively worsened cardiovascular outcomes.

The FDA updates sotatercept's label, enhancing treatment options for pulmonary arterial hypertension and reducing severe clinical events.

Research highlights the link between earlier menopause, cardiac function, and brain health, emphasizing the need for sex-specific dementia risk strategies.

Influenza vaccination provided direct, non–infection-based benefits in older adults.

When treating vasomotor symptoms (VMS), 15- and 20-mg doses of estetrol (E4) did not significantly hinder postmenopausal women’s blood pressure, including those with cardiovascular risks.

Prior to the 2025 American Heart Association (AHA) Scientific Sessions Meeting, Craig J. Beavers, PharmD, FACC, FAHA, FCCP, BCCP, BCPS (AQ-Cardiology), CACP, discusses two recent papers that are influencing practice within the cardiovascular space.